Trial Profile
Association between neurofilament light antibodies in serum and response to natalizumab in patients with multiple sclerosis
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 24 Nov 2015
Price :
$35
*
At a glance
- Drugs Natalizumab (Primary)
- Indications Multiple sclerosis
- Focus Biomarker; Pharmacodynamics
- 24 Nov 2015 New trial record